Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025.
Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo validation and drug discovery to Renovaro's AI powered biomarker and diagnostic platform.
At the core of this potential synergy is BioSymetrics' proprietary Elion platform, a cutting-edge AI and machine learning engine that has been designed to uncover complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics' Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enables patient stratification and drug repurposing. BioSymetrics' advanced in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling, BioSymetrics has amassed a very large database of proprietary in vivo experimentation, with associated behavioral and morphological analysis. This integrated approach potentially hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into Renovaro's workflow, the combined business aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development.
'This merger represents a pivotal step in our mission to diagnose cancer and advance precision medicine,' said David Weinstein, CEO of Renovaro. 'By combining our expertise in oncology with BioSymetrics' expertise in epilepsy and other neurological diseases, we believe that we are creating a powerful synergy that will enhance our ability to identify new therapeutic targets, validate diagnostics and accelerate precision drug development.'
BioSymetrics' AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, Renovaro can now access cutting-edge computational tools that are designed to enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions in oncology and neurology.
'We are excited to join forces with Renovaro to translate cutting-edge biomarker discoveries into tangible advancements in drug development,' said Anthony Iacovone, CEO of BioSymetrics. 'Our AI-driven Elion platform has the potential to significantly impact precision medicine and by aligning with Renovaro's deep expertise in immunotherapy and oncology, we believe that we can accelerate the journey from discovery to clinical application.'
The combination of Renovaro and BioSymetrics underscores a shared commitment to harnessing AI and data-driven approaches to improve patient outcomes. Moving forward, the combined company will focus on integrating AI-powered biomarker discovery with innovative drug development, ultimately intended to bring more precise and effective treatments to patients worldwide.
For more information, visit www.renovarogroup.com and www.biosymetrics.com.
About BioSymetrics
BioSymetrics is a leading AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to identify novel therapeutics. Its proprietary Elion platform integrates large-scale biological and clinical data to drive innovation in the pharmaceutical and healthcare industries. For more information, visit www.biosymetrics.com.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development. For more information, visit www.renovarogroup.com.
Forward-Looking Statements
This press release contains statements by Renovaro Biosciences Inc. ('Renovaro', 'we', 'us', 'our' or the 'Company') that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our prospects, plans, business strategy and expected financial and operational results. You can identify these statements by the use of words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'should,' 'will,' 'would', 'could', 'project', 'plan', 'potential', 'designed', 'seek', 'target', variations of these terms, the negatives of such terms and similar expressions. These statements are based on certain assumptions that we have made in light of our experience in our industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. You should not rely on forward-looking statements because our actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: the success or efficacy of our pipeline, platform and fundraising; our ability to successfully integrate business that we have acquired, including BioSymetrics, or that we may acquire; our ability to achieve the benefits that we expect to realize as a result of our acquisitions, including BioSymetrics; and those other risks and uncertainties discussed in the reports we have filed with the Securities and Exchange Commission (the 'SEC'), such as our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date the statements were made. We do not undertake any obligation to update forward-looking information, except to the extent required by applicable law.
Investor Relations
Chris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@mzgroup.uswww.mzgroup.us
For media inquiries, please contact:karen@renovarocube.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Goldman Sachs Sets $160 Target on Arm Holdings (ARM)—Here's What Investors Should Know
Arm Holdings plc (NASDAQ:) is a . On July 10, Goldman Sachs analyst James Schneider initiated coverage on the stock with a 'Neutral' rating and a price target of $160.00. Goldman Sachs is optimistic that Arm will maintain its lead in the smartphone market, as well as increase its penetration in the data center segment now that hyperscalers are increasingly deploying custom ARM-based CPUs. Another positive factor highlighted by the firm is the anticipation that ARM will leverage the v8 to v9 transition and greater adoption of Compute Subsystems (CSS) to take advantage of increased royalty rates. A financial analyst giving a presentation to a group of investors about annuity insurance. However, the firm believes that both of these factors are already understood by the investors and reflected in the stock price. As such, there is limited upside for the stock. Arm Holdings plc (NASDAQ:ARM) is a semiconductor and software design company that designs and manufactures semiconductor technology and other related products. While we acknowledge the potential of ARM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Business Insider
an hour ago
- Business Insider
JB Hunt (JBHT) Gets a Buy from Benchmark Co.
In a report released on July 10, Christopher Kuhn from Benchmark Co. maintained a Buy rating on JB Hunt, with a price target of $165.00. The company's shares closed last Friday at $153.57. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Kuhn is a 4-star analyst with an average return of 8.3% and a 48.96% success rate. Kuhn covers the Industrials sector, focusing on stocks such as Hub Group, Knight Transportation, and XPO. In addition to Benchmark Co., JB Hunt also received a Buy from Bank of America Securities's Ken Hoexter in a report issued on July 9. However, on July 10, Barclays maintained a Hold rating on JB Hunt (NASDAQ: JBHT). Based on JB Hunt's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.92 billion and a net profit of $117.74 million. In comparison, last year the company earned a revenue of $2.94 billion and had a net profit of $127.49 million Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of JBHT in relation to earlier this year. Most recently, in April 2025, Nicholas Hobbs, the EVP & COO of JBHT bought 3,038.00 shares for a total of $399,738.33.
Yahoo
an hour ago
- Yahoo
These 5 Technology Stocks Are Money-Printing Machines
Large technology companies generate lots of revenue and cash flow. Most return some of their massive cash flows to shareholders via dividends and repurchases. Many also have large and growing cash balances. 10 stocks we like better than Nvidia › The technology sector can be a very profitable industry. Many tech companies generate reliable recurring revenues by selling their software to customers on a subscription basis. Others benefit from durable and growing demand for their products as customers routinely need to upgrade to the latest model. Here are five tech titans that are money-printing machines. Apple (NASDAQ: AAPL) has built an amazing ecosystem of consumer products and related services. It sold a staggering $167 billion of iPhones, iPads, Macs, and other technology products during the first half of the year. It booked another $53 billion in revenue from subscription services like Apple TV+, iCloud, and Apple Music. After expenses, Apple generated $24 billion in operating cash flow during the second quarter alone. It utilized that robust cash flow and its cash-rich balance sheet (over $132 billion in cash, cash equivalents, and marketable securities) to return $29 billion to its shareholders in the quarter via dividends and share repurchases. It recently hiked its dividend by 4% and launched an additional $100 billion share repurchase program. Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) generates massive revenues from online advertising on its Google Search platform and YouTube. It also generates subscription revenue (e.g., Google One), sells devices (e.g., Nest), and has a booming cloud infrastructure business. During the first quarter, Alphabet's businesses generated over $90 billion in revenue. The tech giant produced nearly $19 billion in free cash flow during the first quarter and almost $75 billion over the last 12 months. It paid out $1.2 billion of that money in dividends and repurchased over $15 billion in stock during the first quarter. With it producing more excess cash than it returned to shareholders, the amount of cash, cash equivalents, and marketable securities on its balance sheet rose to nearly $134 billion. Alphabet recently boosted its dividend payment by 5% and authorized an additional $70 billion share repurchase program. Microsoft (NASDAQ: MSFT) has an increasingly diverse business that generates massive revenues and cash flows. It booked more than $70 billion in revenue during its fiscal 2025 third quarter from sources such as Azure cloud, Xbox, LinkedIn, Windows, and AI services. The tech titan has generated nearly $94 billion in net cash from operating activities through the first nine months of its fiscal 2025. It has paid out about $18 billion in dividends and repurchased almost $14 billion of its stock. Even with those hefty cash returns, Microsoft ended the period with almost $80 billion of cash, cash equivalents, and short-term investments on its balance sheet. That supports its ability to continue returning lots of money to shareholders. Microsoft boosted its dividend by 10% last fall and approved a new $60 billion share repurchase program. Meta Platforms (NASDAQ: META) generates massive revenues from advertising on its social media platforms. During the first quarter, it booked more than $41 billion of advertising revenue. It also generated an additional $510 million in other revenue from its "Family of Apps" segment and $412 million in revenue from its Reality Labs segment, which encompasses its virtual reality, augmented reality, and AI platforms. The social media giant's business generated more than $10 billion of free cash flow during the first quarter. It returned almost $15 billion in cash to shareholders during the period through stock repurchases ($13.4 billion) and dividend payments ($1.3 billion). Even with that robust cash return, Meta ended the period with a whopping $70 billion of cash, cash equivalents, and marketable securities on its balance sheet. Nvidia (NASDAQ: NVDA) produces prodigious cash flows by developing and selling graphics processing units (GPUs), many of which are being deployed to support AI applications. It generated $44.1 billion in revenue during the first quarter, an impressive 69% increase compared to the same period last year. The big driver was sales to data center customers, which surged by 73% to $39.1 billion. The AI semiconductor giant generated over $27 billion in cash flow from operations during the first quarter, a 79% increase compared to the same period last year. It returned $14.3 billion to shareholders through stock repurchases ($14.1 billion) and dividends ($244 million). With its free cash flow far outpacing its cash returns, Nvidia's cash balance ballooned to $53.7 billion. That will allow it to continue returning more cash to shareholders. It gave investors a massive 150% dividend hike last year and boosted its stock repurchase program by a whopping $50 billion. These large technology companies have become money printers. They generate mounds of recurring revenue from subscriptions, advertising, and rising demand for their products and services. That enables them to return prodigious amounts of cash to shareholders through growing dividends and meaningful share repurchase programs. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Matt DiLallo has positions in Alphabet, Apple, and Meta Platforms and has the following options: short August 2025 $250 calls on Apple. The Motley Fool has positions in and recommends Alphabet, Apple, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. These 5 Technology Stocks Are Money-Printing Machines was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
